Company news
Satellos Bioscience Inc (TSX:MSCL) news
Satellos Bioscience Inc news releases on 6ix. Latest, Apr 29, 2025: Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
Press releases — page 2
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
April 29, 2025
Satellos to Participate in Two April Investor Conferences
April 2, 2025
Satellos Reports 2024 Financial Results and Highlights Company Progress
March 26, 2025
Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
March 19, 2025
Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
February 18, 2025
Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
February 10, 2025
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.
December 20, 2024
Satellos Bioscience Inc. Opens the Market
May 15, 2024
24/02/13 - TSX Venture Exchange Stock Maintenance Bulletins
February 14, 2024
Satellos to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
September 20, 2023
Satellos Bioscience Enters Into an Agreement with ICP Securities Inc. to Provide Market Making Services
September 7, 2023
Satellos Expands Leadership Team with New CFO Appointment
September 5, 2023
Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights
August 29, 2023
TSX Venture Exchange, Satellos Bioscience Inc., View From The C-Suite
August 21, 2023
Satellos Bioscience Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy
August 2, 2023
Satellos Bioscience Announces Results from Its Annual General Meeting of Shareholders and Adoption of Amendments to Stock Option Plan
June 30, 2023
Satellos Bioscience Announces Appointment of Chief Medical Officer
June 7, 2023
Satellos Bioscience Announces Grant of Stock Options
June 1, 2023
Satellos Bioscience Announces 2023 Q1 Financial Results and Operational Highlights
May 30, 2023
Satellos Bioscience Closes $55M Financing to Support Development of its Lead Drug Candidate for Duchenne Muscular Dystrophy
May 17, 2023
Satellos Bioscience Inc. Announces Filing of Final Short Form Prospectus for Proposed Offering of Common Shares
May 10, 2023
IIROC Trading Resumption - MSCL
April 19, 2023
Satellos Bioscience Inc. Announces Pricing of Public Offering
April 19, 2023
IIROC Trading Halt - MSCL
April 19, 2023
Satellos Bioscience Inc. Announces Public Offering of Common Shares
April 18, 2023
Satellos Bioscience Announces 2022 Year End Financial Results and Operational Highlights
March 29, 2023
Satellos Bioscience Announces Closing of Previously Announced Non-Brokered Offering of $2.385 Million of Unsecured Non-Convertible Debentures
March 29, 2023
Satellos Bioscience Announces Upsize of Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures to up to $2.385 Million
March 21, 2023
Satellos Bioscience to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor Summit
March 17, 2023
Satellos Bioscience Announces Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures of up to $2.25 Million
March 15, 2023
Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 As a Potential Treatment for Duchenne Muscular Dystrophy
March 10, 2023
Satellos Bioscience Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model
February 6, 2023
Satellos Bioscience Announces Development Candidate
January 3, 2023
Satellos Bioscience Announces Q3 2022 Financial Results and Operational Highlights
November 23, 2022
Satellos Bioscience Announces Advancement of Compounds to Next Stage of Development
November 3, 2022
Satellos Bioscience Inc. to Present Preliminary Preclinical Proof of Concept Data for an Additional Rare Disease at World Muscle Society Meeting
October 11, 2022
Satellos Bioscience Inc. Announces Licensing of Formulation Technology and Expanded Collaboration with NW PharmaTech Ltd.
October 6, 2022
Satellos Bioscience Announces OTCQB Listing in the United States
October 6, 2022
Satellos Bioscience Inc. Announces the Grant of Stock Options
October 5, 2022
Satellos Bioscience Inc. Announces the Appointment of Philip D. Lambert, Ph.D, as Chief Technology Officer
September 28, 2022
Satellos Bioscience Inc. Announces Closing of Offering of Units
September 13, 2022
Satellos Bioscience Inc. Announces the Filing of Final Short Form Prospectus for Proposed Offering of Units
September 7, 2022
Satellos Bioscience Inc. Announces Pricing of Proposed Offering of Units
August 29, 2022
Satellos Bioscience Reports Q2 2022 Financials and Operating Results
August 29, 2022
Satellos Bioscience Inc. Announces the Filing of an Amended and Restated Preliminary Prospectus for Proposed Offering of Units
August 28, 2022
Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Awarded Significant Grant from the Canadian Institutes of Health Research
July 25, 2022
Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Published in Nature Communications
July 13, 2022
Satellos Bioscience Inc. Announces Proposed Offering of Units
July 11, 2022
Satellos Bioscience Announces In-Licensing of New Patent Application
June 29, 2022
Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Officially Recognized as a Fellow of the Royal Society
June 22, 2022